ZyVersa Therapeutics Adds Dr. Richard J. Glassock to Its Renal Scientific Advisory Board to Support Clinical Advancement of Renal Cholesterol Efflux Mediator™ VAR 200
March 07, 2023 09:20 ET
|
ZyVersa Therapeutics
Cholesterol Efflux Mediator VAR 200 is a phase 2a-ready drug in development to ameliorate renal lipid accumulation that damages the kidneys’ filtration system, leading to progression of kidney disease...
ZyVersa Therapeutics to Participate in a Fireside Chat at Oppenheimer Healthcare Conference
March 01, 2023 09:20 ET
|
ZyVersa Therapeutics
CEO Stephen C. Glover to discuss key updates on the development status of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for renal disease, and inflammasome ASC inhibitor IC 100 for...
ZyVersa Therapeutics to Participate in a Fireside Chat at Roth Annual Conference
February 27, 2023 09:20 ET
|
ZyVersa Therapeutics
CEO Stephen C. Glover to discuss key updates on the development status of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for renal disease, and inflammasome ASC inhibitor IC 100 which...
ZyVersa Therapeutics Announces New Publication in Translational Research Showing IC 100 Reduces Inflammasome Activation in Mouse Model for Alzheimer’s Disease Following Traumatic Brain Injury
February 23, 2023 09:20 ET
|
ZyVersa Therapeutics
Data published in Translational Research indicate that pyroptotic release of cytokines and ASC Specks from traumatic brain injury (TBI) induces a heightened inflammasome response in Alzheimer’s...
ZyVersa Therapeutics Reports Inducement Grant to Newly Appointed Chief Medical Officer Under Nasdaq Listing Rule 5635(c)(4)
January 27, 2023 16:00 ET
|
ZyVersa Therapeutics
WESTON, Fla., Jan. 27, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for...
ZyVersa Therapeutics to Present at BIO CEO & Investor Conference
January 25, 2023 09:45 ET
|
ZyVersa Therapeutics
CEO Stephen C. Glover to provide key updates on the development status of ZyVersa’s Phase 2a-ready cholesterol efflux mediator VAR 200 for renal disease and inflammasome ASC inhibitor, IC 100 WESTON,...
ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Present at the Virtual Investor 2023 Companies to Watch Event
January 11, 2023 14:45 ET
|
ZyVersa Therapeutics
Live video webcast on Wednesday, January 18th at 2:00 PM ET Mr. Glover will highlight the development status of ZyVersa’s phase 2a-ready VAR 200 for renal disease and inflammasome ASC inhibitor, IC...